Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neopath (NPTH) -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (155)	6/12/1998 1:44:00 PM
From: Frank Buck	Read Replies (1) \| Respond to of 178

Doesn't this fly in the face of this recent news..... By Louis Hau, Staff Reporter NEW YORK -(Dow Jones)- The federal agency that runs the Medicare program has proposed allowing a separate reimbursement for second inspections of abnormal Pap smears. Industry observers say the new guideline could INCREASE THE NUMBER OF LABORATORIES that process the cervical-cancer test, which, in turn, could POTENTIALLY BENEFIT companies that make Pap-smear products.The Health Care Financing Administration currently permits reimbursement of up to $7.15 for the screening of Pap smears. The proposed change, published in Friday's Federal Register, would permit separate reimbursement at an average of $28.62 for a second inspection of suspicious slides that result in abnormal readings. Abnormal readings can indicate cervical cancer, precancerous lesions that could lead to the disease, or benign cellular abnormalities.